# Effect of poor glycemic control in cognitive performance in the elderly with type 2 diabetes mellitus: The Mexican Health and Aging Study

A. J. Mimenza-Alvarado, G. A. Jimenez-Castillo, S. G. Yeverino-Castro, A. J.

Barragan-Berlanga, M. U. Perez-Zepeda, Jose Alberto Avila-Funes, S. G.

Aguilar-Navarro

► To cite this version:

A. J. Mimenza-Alvarado, G. A. Jimenez-Castillo, S. G. Yeverino-Castro, A. J. Barragan-Berlanga, M. U. Perez-Zepeda, et al. Effect of poor glycemic control in cognitive performance in the elderly with type 2 diabetes mellitus: The Mexican Health and Aging Study. BMC Geriatrics, 2020, 20 (1), pp.424. 10.1186/s12877-020-01827-x. doi:10.1186/s12877-020-01827-x

HAL Id: hal-03132503

https://hal.science/hal-03132503

Submitted on 5 Feb 2021

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH ARTICLE

Open Access

# Effect of poor glycemic control in cognitive performance in the elderly with type 2 diabetes mellitus: The Mexican Health and Aging Study

<figure><img src="image_2.png" /></figure>

Check for
updates

Alberto J. Mimenza-Alvarado<sup>1,2</sup>, Gilberto A. Jiménez-Castillo<sup>1,2,3</sup>, Sara G. Yeverino-Castro<sup>1</sup>,
Abel J. Barragán-Berlanga<sup>3</sup>, Mario U. Pérez-Zepeda<sup>4</sup>, J. Alberto Ávila-Funes<sup>5</sup> and Sara G. Aguilar-Navarro<sup>1,2*</sup>

Abstract

**Background:** Cognitive impairment is twice more frequent in elderly with type 2 diabetes mellitus (DM). This study was conducted to determine the association between glycemic control and cognitive performance among community-dwelling elderly persons in Mexico.

**Methods:** Cross-sectional study conducted in individuals aged 60 years or elderly participating in the 2012 Mexican Health and Aging Study. Type 2 DM participants were classified in 3 groups according to their glycated hemoglobin levels (HbA1c): < 7% (intensive control), 7-7.9% (standard control) or ≥ 8% (poor control), and cognitive performance: low (CCCE ≤44 points), intermediate (44.1-59.52 points), or high (≥59.53 points). Multinomial logistic regression models were constructed to determine this association.

**Results:** Two hundred sixteen community-dwelling adults aged 60 and older with type 2 diabetes were selected. Subjects in the low cognitive performance group were older (69.7 ± 6.6 vs 65.86 ± 5.18 years, *p* < .001) and had a lower educational level (2.5 ± 2.6 vs 7.44 ± 4.15 years, *p* < .000) when compared to the high cognitive performance participants. HbA1c ≥ 8% was associated with having low (Odds Ratio (OR) 3.17, 95% CI 1.17–8.60, *p* = .024), and intermediate (OR 3.23, 95% CI 1.27–8.20, *p* = .014) cognitive performance; this trend was not found for HbA1c 7.0–7.9% group.

The multinomial regression analysis showed that the presence of HbA1c ≥ 8% (poor glycemic control) was associated with low (OR 3.17, 95% CI = 1.17–8.60, *p* = .024), and intermediate (OR 3.23, 95% CI = 1.27–8.20, *p* = .014) cognitive performance. After adjusting for confounding variables.

**Conclusions:** Glycemic control with a HbA1c ≥ 8% was associated with worse cognitive performance.

**Keywords:** Glycemic control, Cognitive performance, Elderly persons, Type 2 diabetes mellitus

<footnote>* Correspondence: sgan30@hotmail.com</footnote>

<footnote n="1">¹Geriatric Medicine & Neurology Fellowship, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, 14000 Mexico City, Mexico</footnote>

<footnote n="2">²Department of Geriatric Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15. Tlalpan, 14000 Mexico City, Mexico</footnote>

<footnote>Full list of author information is available at the end of the article</footnote>
## Background

Type 2 Diabetes Mellitus (DM) rates and its complications are increasing faster than expected. Prevalence increased from 4.3 to 9.0% in men and 5.0 to 7.9% in women from 1980 to 2014. By year 2025, diabetes would exceed 700 million cases. Thus, 37.9% of the rising prevalence is due to population growth and ageing [1]. In our country, Mexican National Health and Nutrition Survey (ENSANUT) reported a DM prevalence of 27.4% in the geriatric population [2]. The increasing prevalence of diabetes will lead to a higher number of people with diabetes-related cognitive impairment. For this reason, efforts to control not only type 2 DM, but hypertension, depression and other risk factors are essential for dementia prevention around the world [3, 4].

Numerous reports have shown that patients with DM are at increased risk of Alzheimer's disease (AD) dementia and vascular dementia [5]. It is currently accepted that worldwide type 2 DM increases 1.5 to 3 times the risk of dementia [6]. The Rotterdam study was one of the first population-based studies to examine the relationship between type 2 DM and cognitive impairment. It reported an increased risk of 1.9 (95% CI: 1.3–2.8) for this population [7]. In Mexico, a longitudinal study which included data from the Mexican Health and Aging Study (MHAS) reported a relative risk for cognitive impairment of 2.08 (95% CI: 1.59–2.73) among type 2 DM in elderly [8].

An optimal glycemic control is needed to prevent or reduce type 2 DM complications such as nephropathy, retinopathy, neuropathy and cognitive disorder. Although, epidemiologic studies have associated poor type 2 DM control with cognitive decline, clinical evidence about glycemic control goals for type 2 DM in elderly is contradictory and lacking. The American Diabetes Association (ADA) 2019 guidelines suggest a reasonable glycated hemoglobin (HbA1c) goal of < 7% for most patients and a less stringent < 8% for those with limited life expectancy or multiple comorbid conditions [9, 10]. The American Geriatric Society (AGS) recommends a HbA1c goal < 7.5% for healthy population; while for the complex or comorbid and functional-dependent patient the aim should be a HbA1c of < 8% [11]. According to these guidelines, HbA1c goals are based on two variables, which must be considered before a decision: cognitive and functional status. Thus, in both guidelines HbA1c goal recommendation is < 8% for subjects with mild to moderate cognitive impairment [9–11].

ADA 2019 guideline recommendations on a HbA1c goal below or greater than 8% are lacking on making a clear reference on the risk of adverse effects and cognitive impairment progression. Studies, such as the Memory in Diabetes (MIND) substudy of the Action to Control Cardiovascular Risk Diabetes (ACCORD), which

has been one of the most influential when concerning glycemic goals found no difference in cognitive outcomes with either HbA1c < 6% or 7.0–7.9 [12]. This study could provide different insights towards the appraisal of cognitive impairment through knowledge of type 2 DM, one of its main risk factors. Although, cultural variances could be noted as environmental factors carry a great weight on the disease; glycemic control is a parameter that could be standardized across countries. The aim of the present study was to determine the association between glycemic control and cognitive performance among Mexican rural and urban community-dwelling older adults analyzed in the MHAS round 2012.

## Methods

### Study population

Data was obtained from the MHAS, a large, national representative panel study of older Mexicans (age 50 or older) and their spouses. Briefly, the aim and design of MHAS has to evaluate its participants health and cognitive characteristics. The study started in 2001 and has four follow-ups (2003, 2012, 2015 and 2018). Information from a subsample of subjects who participated in 2012 wave was used for the present study. Data was assessed through performance test, anthropometric measures and blood samples; included HbA1c, among others [13, 14]. Additional information can be found at: http://www.mhasweb.org/ [15].

### Sample selection

The 2012-MHAS round included 15,723 subjects (aged 50 and over). For the present study, people aged 60 years or older with complete information from cognitive tests (7469 subjects) and available HbA1c biomarker measurements (946 subjects) were required.

Type 2 DM was considered when a positive answer was given to the following question: "Has a doctor ever told you or given you a diagnosis of diabetes mellitus?". Fasting glucose levels and the use of antidiabetic drugs were not considered. According to HbA1c levels: 141 (14.9%) without diabetes (HbA1c: < 5.5%), 407 (43%) with prediabetes (HbA1c: 5.5–6.4%), 182 (19, 2%) had undiagnosed DM (HbA1c ≥ 6.5%) and only 216 (22.8%) had history of type 2 DM and available HbA1c (Fig. 1).

### Glycemic control

Glycemic control was established as an independent variable, data available in the MHAS database section I, it consists of a single measurement of HbA1c was measured in the MHAS with the A1c-now test kit, an immunoassay device. This method in comparison to the standard liquid chromatography test has a sensitivity of 91.9 to 100%, and a specificity of 66.7 to 82.4% [16].
<figure><img src="image_3.png" /><figcaption>**Fig. 1** Flowchart of sample selection, MHAS: Mexican Health Aging Study 2012</figcaption></figure>

Of note, pre-prandial capillary glucose was not available for the analysis. Glycemic control categories were defined based on the cut-off points used in the ADA and ACCORD-MIND studies [9, 12]. The following glycemic control groups were defined: intensive ($Hb_{A1c} < 7\%$), standard ($Hb_{A1c} 7–7.9\%$), and poor ($Hb_{A1c} \ge 8\%$).

Glycemic control categories were defined based on the cut-off points used in the ADA and ACCORD-MIND studies [9, 12]. The following glycemic control groups were defined: intensive ($Hb_{A1c} < 7\%$), standard ($Hb_{A1c} 7–7.9\%$), and poor ($Hb_{A1c} \ge 8\%$).

## Cognitive performance

In order to determine the cognitive status, all participants underwent the Cross-Cultural Cognitive Examination (CCCE). The CCCE, was selected for both its transcultural attributes (responses are not influenced by education, language or culture) and concurrent validity, which in comparison to other common cognitive instruments, has a 94% specificity and 99% sensitivity for the detection of cognitive impairment [17]. Total CCCE scores consist of a sum of maximum 99 points. For direct respondents, the MHAS assesses cognitive function through a modified version CCCE; which measures performance in eight cognitive domains—verbal learning,

delayed memory, attention, constructional praxis, visual memory, verbal fluency, orientation, and processing speed—and has reference norms by age and education [18]. In order to determine the association between cognitive performance level and glycemic control and as a strategy for the abnormal distribution of the data, the total CCCE score was classified by tertiles where the highest represents a better cognitive performance and vice versa. Therefore, cognitive performance was defined as low (CCCE ≤44 points), intermediate (44.1–59.52 points), and high (≥59.53 points). This was the dependent variable for the study.

## Covariables

Age, sex and level of education were the only sociodemographic variables analyzed. Participants' positive responses to the questions: Has a doctor ever told you that you have ... [i.e. smoking history, alcoholism, hypertension, cerebrovascular disease (CVD), and ischemic heart disease (IHD), were considered as for the subjects' clinical characteristics. Obesity was considered when the subject's body mass index (BMI) was ≥30 kg/m² [19]. Further, five cardiovascular comorbidities or categoric variables were grouped as a compound or sum in order to construct a continuous variable. The presence of
hypertension, smoking history, CVD, obesity or previous heart disease added one point each to the comorbidity score. A score of 5 represents the highest level of cardiovascular morbidity, while 0 equals no comorbidity.

Depressive symptoms were classified as high for scores ≥5 in a modified version of the *Center for Epidemiologic Studies Depression Scale* (CES-D) validated in Mexico [20]. Blood pressure and heart rate measurements, as well as C-reactive protein, total cholesterol, high density cholesterol (HDL), thyroid stimulating hormone (TSH), and vitamin D levels were also analyzed.

## Statistical analysis

Categorical and continuous variables were analyzed with chi-squared and ANOVA, respectively. Multinomial logistic regression models were used to determine the association between glycemic control and cognitive performance and adjusted by several potential confounders including age, educational level, blood pressure, TSH, C-reactive protein and vitamin D blood levels, depressive symptoms, and the comorbidities score. Statistical significance was considered at a *p* value ≤.05 and 95% confidence intervals (CI) were given. Statistical analysis was performed using SPSS software for Windows® (SPSS Inc., Chicago, IL version 23.0).

## Results

From a total of 216 participants with type 2 DM were included in the analysis, the mean age was 68.11 (± 6.4) years, 57.9% were female, and the mean education level was 4.72 (± 3.9) years. Type 2 DM participants also had a high prevalence of hypertension (69%) and IHD (7.9%). Obesity was reported in 40% of the participants. Smoking history was present in 9.7% and alcohol history in 18.1%. The mean score for depressive symptoms was 4.76 (± 1.9) points. Mean HbA1c blood level value was

8.34 ± 2.05%. When divided by glycemic control groups, no differences were found in any of the variables analyzed (Table 1).

As shown in Table 2, were classified as having low (35.1%), intermediate (31.4%) or high (33.3%) cognitive dysfunctions. Subjects in the lower cognitive performance group were older (69.7 ± 6.6 years vs 65.86 ± 5.18 *p* < .001) and had a lower educational level (2.5 ± 2.6 years vs 7.44 ± 4.15; *p* < .000) when compared to the high cognitive performance participants. No significant differences between the three groups were found for any of the other clinical variables, except for alcoholism, which was more frequent in the intermediate cognitive performance group (27.9%, *p* = .023).

When compared to the intensive glycemic control group those with poor glycemic control had a borderline association with worse cognitive performance in the unadjusted regression model. After adjusting for confounding variables, the multinomial regression analysis showed that the presence of HbA1c ≥ 8% (poor glycemic control) was associated with low (Odds Ratio (OR) 3.17, 95% CI = 1.17–8.60, *p* = .024), and intermediate (OR 3.23, 95% CI = 1.27–8.20, *p* = .014) cognitive performance. This trend was not found for the standard glycemic control (HbA1c 7–7.9%) (Table 3).

## Discussion

In our study of community-dwelling older Mexican adults with type 2 DM, a poor glycemic control (HbA1c ≥ 8%) was associated with worse cognitive performance when compared to intensive control group. The uncontrolled type 2 DM group had a positive association with overall low cognitive performance, while the standard controlled population (HbA1c 7–7.9%) did not show an association.

<table><caption>**Table 1** Sociodemographic, health status and glycemic control of the study sample. MHAS 2012</caption><thead><tr><th rowspan="2">Mean (SD)/nn/SD(%)</th><th>Total</th><th>Intensive Glycemic Control<br>HbA1c &lt; 7.0%</th><th>Standard Glycemic Control<br>HbA1c 7.0–7.9%</th><th>Poor Glycemic Control<br>HbA1c ≥ 8%</th><th rowspan="2">P</th></tr><tr><th>n = 216</th><th>n = 67</th><th>n = 46</th><th>n = 103</th></tr></thead><tbody><tr><td>Age</td><td>68.11 (6.48)</td><td>68.82 (6.92)</td><td>68.02 (6.96)</td><td>67.69 (5.98)</td><td>.538</td></tr><tr><td>Female</td><td>125 (57.9%)</td><td>37 (52.22%)</td><td>23 (50.0%)</td><td>65 (63.1%)</td><td>.284</td></tr><tr><td>Education level</td><td>4.72 (3.96)</td><td>4.72 (3.81)</td><td>4.74 (3.51)</td><td>4.72 (4.28)</td><td>.999</td></tr><tr><td>Smoking history</td><td>21 (9.7%)</td><td>7 (10.5%)</td><td>5 (10.9%)</td><td>9 (8.7%)</td><td>.895</td></tr><tr><td>Alcoholism</td><td>39 (18.1%)</td><td>13 (19.4%)</td><td>9 (19.6%)</td><td>17 (16.5%)</td><td>.852</td></tr><tr><td>Hypertension</td><td>149 (69.0%)</td><td>44 (65.7%)</td><td>30 (65.2%)</td><td>75 (72.8%)</td><td>.508</td></tr><tr><td>CVD</td><td>4 (1.9%)</td><td>1 (1.5%)</td><td>1 (2.2%)</td><td>2 (1.9%)</td><td>.962</td></tr><tr><td>Obesity</td><td>87 (40.3%)</td><td>30 (44.8%)</td><td>17 (37.0%)</td><td>40 (38.8%)</td><td>.649</td></tr><tr><td>Depressive Symptoms</td><td>4.76 (1.97)</td><td>4.64 (2.32)</td><td>4.61 (1.78)</td><td>4.91 (1.79)</td><td>.569</td></tr><tr><td>IHD</td><td>17 (7.9%)</td><td>7 (10.4%)</td><td>4 (8.7%)</td><td>6 (5.8%)</td><td>.535</td></tr></tbody></table>

Data are presented as means or percentage, ANOVA analysis was performed. CVD Cerebrovascular Disease, IHD Ischemic Heart Disease, SD Standard Deviation
<table><caption>**Table 2** Cognitive Performance, clinical characteristics and glycemic control data of the study sample. MHAS 2012</caption><thead><tr><th>Cognitive Performance</th><th>Total</th><th>Low<br>≤44.0</th><th>Intermediate<br>44.1–59.52</th><th>High<br>≥59.53</th><th>P</th></tr><tr><th>Mean (SD)/nn/SD (%)</th><th>n = 216</th><th>n = 76</th><th>n = 68</th><th>n = 72</th><th></th></tr></thead><tbody><tr><td>Age</td><td>68.11 (6.48)</td><td>69.75 (6.66)<sup>a</sup></td><td>68.66 (6.93)</td><td>65.86 (5.18)</td><td>.001*</td></tr><tr><td>Female</td><td>125 (57.9%)</td><td>49 (64.5%)</td><td>36 (52.9%)</td><td>40 (55.6%)</td><td>.337</td></tr><tr><td>Education level</td><td>4.72 (3.96)</td><td>2.57 (2.67)<sup>ab</sup></td><td>4.25 (3.27)</td><td>7.44 (4.15)</td><td>.000*</td></tr><tr><td>Smoking history</td><td>21 (9.7%)</td><td>7 (9.2%)</td><td>6 (8.8%)</td><td>8 (11.1%)</td><td>.887</td></tr><tr><td>Alcoholism</td><td>39 (18.1%)</td><td>8 (10.5%)<sup>a</sup></td><td>19 (27.9%)</td><td>12 (16.7%)</td><td>.023*</td></tr><tr><td>Hypertension</td><td>149 (69.0%)</td><td>54 (71.1%)</td><td>49 (72.1%)</td><td>46 (63.9%)</td><td>.519</td></tr><tr><td>CVD</td><td>4 (1.9%)</td><td>3 (3.9%)</td><td>1 (1.5%)</td><td>0 (0.0%)</td><td>.199</td></tr><tr><td>Obesity</td><td>87 (40.3%)</td><td>27 (35.5%)</td><td>28 (41.2%)</td><td>32 (44.4%)</td><td>.537</td></tr><tr><td>Depressive Symptoms</td><td>4.76 (1.97)</td><td>5.04 (1.91)</td><td>4.81 (2.08)</td><td>4.43 (1.89)</td><td>.166</td></tr><tr><td>IHD</td><td>17 (7.9%)</td><td>5 (6.6%)</td><td>7 (10.3%)</td><td>5 (6.9%)</td><td>.670</td></tr><tr><td>Systolic Pressure</td><td>144.67 (21.72)</td><td>145.54 (22.83)</td><td>147.68 (21.83)</td><td>140.93 (20.10)</td><td>.169</td></tr><tr><td>Diastolic Pressure</td><td>77.67 (12.20)</td><td>76.68 (12.97)</td><td>79.75 (12.46)</td><td>76.75 (10.96)</td><td>.237</td></tr><tr><td>Heart Rate</td><td>76.71 (12.16)</td><td>76.28 (12.67)</td><td>78.90 (12.75)</td><td>75.10 (10.85)</td><td>.169</td></tr><tr><td>PCR</td><td>4.68 (7.20)</td><td>4.78 (7.28)</td><td>4.98 (8.54)</td><td>4.30 (5.68)</td><td>.854</td></tr><tr><td>Total Cholesterol</td><td>192.64 (41.88)</td><td>194.16 (37.94)</td><td>196.46 (55.01)</td><td>187.50 (29.13)</td><td>.431</td></tr><tr><td>HDL</td><td>38.38 (8.81)</td><td>36.86 (8.12)</td><td>38.60 (9.28)</td><td>39.74 (8.93)</td><td>.144</td></tr><tr><td>TSH</td><td>3.35 (8.38)</td><td>3.64 (11.59)</td><td>4.14 (8.35)</td><td>2.31 (1.95)</td><td>.416</td></tr><tr><td>Vitamin D</td><td>21.13 (6.83)</td><td>20.85 (7.40)</td><td>20.94 (6.40)</td><td>21.60 (6.67)</td><td>.779</td></tr><tr><td>Glycemic Control</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Poor<br>Hb<sub>A1c</sub> ≥ 8%</td><td>103 (47.7%)</td><td>41 (54.0%)</td><td>36 (52.9%)</td><td>26 (36.1%)</td><td>.166</td></tr><tr><td>Standard<br>Hb<sub>A1c</sub> 7.0–7.9%</td><td>46 (21.3%)</td><td>13 (17.1%)</td><td>15 (22.1%)</td><td>18 (25%)</td><td></td></tr><tr><td>Intensive<br>Hb<sub>A1c</sub> < 7.0%</td><td>67 (31.0%)</td><td>22 (28.9%)</td><td>17 (25%)</td><td>28 (38.9%)</td><td></td></tr></tbody></table>

Data are presented as means or percentage, ANOVA analysis was performed. CVD Cerebrovascular Disease, IHD Isquemic Heart Disease, PCR Reactive protein-C, HDL High density cholesterol, TSH Stimulating thyroid hormone, HbA1c Glycated hemoglobin, SD Standard Deviation. *p ≤ 0.05. Post-hoc DSM $^{a}$p < 0.001 Low vs High cognitive performance; $^{b}$p < 0.001 Low vs Intermediate cognitive performance

A high HbA1c level (> 10%) is associated with an increased risk of all type dementia (HR 1.20, 95% CI 1.07–1.35) [21]. However, studies that analyze glycemic control, specifically, HbA1c levels ≥8% and their association with cognitive performance, are scarce. After a sub-analysis, a US prospective study of 5099 participants showed an association between HbA1c

levels (≥8% and 7–7.9%) and mild cognitive impairment (MCI) measured by proxy (Hazzard Risk (HR) 1.89, CI 95% 1.14–3.14, *p* < 0.05 and HR 1.65, CI 95% 1.13–2.42, *p* < 0.01, respectively) in an older adult population [22]. Our results support these association, as an HbA1c ≥ 8% was associated with worse cognitive performance.

<table><caption>**Table 3** Logistic regression analysis in comparison with the reference group</caption><thead><tr><th rowspan="2"></th><th colspan="3">Low Cognitive Performance</th><th colspan="3">Intermediate Cognitive Performance</th></tr><tr><th>Odds Ratio</th><th>95% CI</th><th>p</th><th>Odds Ratio</th><th>95% CI</th><th>p</th></tr></thead><tbody><tr><td>Unadjusted Model</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Poor Control Group (HbA1c > 8%)</td><td>2.01</td><td>0.95–4.22</td><td>.066</td><td>2.28</td><td>1.04–5.00</td><td>.040*</td></tr><tr><td>Standard Control Group (HbA1c 7–7.9%)</td><td>0.92</td><td>0.37–2.27</td><td>.812</td><td>1.37</td><td>0.55–3.42</td><td>.496</td></tr><tr><td>Adjusted Model</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Poor Control Group (HbA1c > 8%)</td><td>3.17</td><td>1.17–8.60</td><td>.024*</td><td>3.23</td><td>1.27–8.20</td><td>.014*</td></tr><tr><td>Standard Control Group (HbA1c 7–7.9%)</td><td>1.15</td><td>0.37–3.62</td><td>.812</td><td>1.57</td><td>0.60–4.41</td><td>.391</td></tr></tbody></table>

High cognitive performance and intensive glycemic control were considered as the reference groups. HbA1c: Glycated Hemoglobin. Confounding variables: age, educational level. CI: Confidence Interval. *p ≤ 0.05
Multiple studies have identified that an intensive vs a standard glycemic treatment had no beneficial or detrimental effects on cognition [12, 23, 24]. A meta-analysis involving five studies, that included 24,297 participants, found that neither intensive (HbA1c 6.0–7.0%) nor standard (HbA1c 7.1–8.0%) glycemic control, when compared to each other, had significant cognitive decline rates (SMD = 0.02; 95% CI = -0.03 to 0.08) [25]. One of the studies mentioned above included, where guideline recommendations are based mostly is the ACCORD-MIND study. Two thousand nine hundred seventy-seven participants (aged 55–80 years) with higher HbA1c levels (> 7.5%) were randomly assigned to an intensive treatment goal (HbA1c < 6.0%) or a standard strategy (HbA1c: 7.0–7.9). In this North American trial, as previously, authors found no difference when comparing cognitive outcomes between groups after 40-week treatment, establishing a greater amplitude of therapy goal for patients [12]. In our study, we were not able to find an association between standard glycemic control (HbA1c 7–7.9%) and low cognitive performance, supporting the previously reported analysis.

Several studies have evaluated the impact of type 2 DM on cognition; however, methodological differences are noted [25]. Data from the English Longitudinal Study of Ageing (ELSA) showed in 5189 participants, a longitudinal association between HbA1c levels and a rate of change in cognitive scores, where 1 mmol/mol increment in HbA1c was significantly associated with increased rate of decline in global cognitive z scores (–0.0009 SD/ year, 95% CI -0.0014, –0.003, *p* 0.002) [26]. Our study provides an association of glycemic control levels and global cognitive performance supporting the data mentioned above; unlike other studies, additional specific HbA1c goals are analyzed and type 2 DM is not taken as a single entity.

After several studies of diabetes and cognitive impairment, authors have gone as far as proposing the possibility of type 3 of DM. Chronic hyperglycemia contributes to conditions such as inflammation, accumulation of advanced glycation end products, and oxidative stress, which in turn lead to cognitive impairment [27]. Studies have shown that persons with DM experience a progressive cognitive decline, particularly characterized by a lower psychomotor speed and alterations in cognitive domains such as attention and executive function [28]. Disruption in glucose metabolism leads to lower cognitive dysfunctions through different mechanisms; a) GLUT transporter altered sensitivity, b) insulin resistance, and c) vascular dysfunction. Chronic hyperglycemia is a phenomenon that inhibits brain autoregulation since GLUT transporters diminish their function in order to protect neurons from an increased glucose influx. When glucose is restored to a normal level, GLUT

transporters fail to recover, causing an absence of intra-neuronal glucose in a process called neuroglycopenia [29]. Insulin resistance could lead to apoptosis by disruption of a secondary pathway; insulin receptor phosphorylation which disrupts long term potentiation, thus increasing inflammation and generating oxidative stress [30]. Vascular homeostasis is also affected by type 2 DM. The presence of atherosclerotic plaques, endothelial dysfunction, increased shear stress, inflammation, impaired vasodilation, and increased vasoconstriction, are some of the mechanisms that lead to vascular injury. The theories presented above, often converge into a type 3 DM diagnosis [31, 32].

The combination of factors seen in the type 2 DM population (hypertense, obese, IHD) mirrors the population's clinical characteristics that physicians are set to treat in the present and near future. As type 2 DM control is one of the strongest modifiable comorbidities that affect brain function, hypertension and obesity are equally relevant risk factors to target. Since currently there are no therapies to cure dementia, the treatment of modifiable risk factors should be emphasized [2, 3].

Some other factors may impact the glycemic control in older adults. In our study, type 2 DM participants with low cognitive performance were older and had a lower educational level. Studies have shown that age is the most important and non-reversible risk factor for the development of cognitive dysfunctions [33]. In elderly adults, pharmacologic management with multiple drugs leads to a low treatment adherence, given a higher number of side effects. Besides, non-pharmacologic treatments such as a diet and lifestyle interventions are generally less effective, since the modification of eating and physical activity habits is usually a difficult task [34, 35]. Education has previously been described as a protective factor for cognitive impairment, as higher education allows the development of “cognitive reserve” and a lower educational level is associated with a 5.6 greater risk of dementia [36]. Also, a lower educational level could influence glycemic control. Adherence to treatment and lifestyle recommendations, disease complications, and awareness are some of the variables in which a lower educational level, over time, has a negative impact [37, 38].

Our study has several limitations. The cross-sectional nature of this study is a major limitation for making cause-effect statements. Also, since the MHAS data was gathered through a survey, many subjects were excluded because there was a lack of biomarker availability. In addition, only a small sample of the cohort was analyzed as we sought to study fulfill the diagnosis of diabetes in community dwelling residents; this could lead to low statistical power and limiting the external validity of the results. Regarding type 2 DM, diagnosis was limited to one HbA1c measurement. A history of duration in years and information on previous control strategies was not
obtained. Nevertheless, our study has several strengths. The MHAS is a large representative sample of community older adults; considering that control of cognitive impairment risk factors is a primary prevention strategy that should be prioritized.

## Conclusions

Our study shows a HbA1c value ≥8% in older adults with diabetes is associated with a worse cognitive performance. Adequate glucose control should also be promoted in older adults.

## Abbreviations

ACCORD-MIND: The Memory in Diabetes (MIND) sub study of the Action to Control Cardiovascular Risk in Diabetes (ACCORD); ADA: American Diabetes Association; CCCE: Cross-Cultural Cognitive Examination; CVD: Cerebrovascular disease; DM: Diabetes Mellitus; ELSA: English Longitudinal Study of Ageing; GLUT: Glucose transporter; HbA1c: Glycated Hemoglobin; HDL: High Density Cholesterol; IHD: Ischemic Heart Disease; MCI: Mild Cognitive Impairment; MHAS: Mexican Health and Aging Study; TSH: Thyroid stimulating hormone

## Acknowledgements

None.

## Declarations

None of the authors have any conflict of interest.

## Authors' contributions

AJMA, SGAN, and JGJC designed the study. AJBB and JGJC searched the literature. AJMA, SGAN, SGYC collected and analyzed the data. MUPZ, JAAF y SGAN interpreted the data. JGJC and SGYC wrote the manuscript draft. All authors (AJMA, JGJC, SGYC, AJBB, MUPZ, JAAF, SGAN) revised the manuscript and approved it for submission.

## Funding

This work was supported by the Mexican Consejo Nacional de Ciencia y Tecnología (CONACYT) (FOSISS 2017-1 290406 2017. GER-2416-18-20-1) who supported the design of the study and the dissemination and publication of the results obtained.

## Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Ethics approval and consent to participate

The Institutional Review Boards or Ethics Committees of the University of Texas Medical Branch in the United States, the Instituto Nacional de Estadística y Geografía, the Instituto Nacional de Salud Pública and the Instituto Nacional de Geriatría in Mexico approved the study. All study subjects signed an informed consent form. The MHAS (Mexican Health and Aging Study) is partly sponsored by the National Institutes of Health/National Institute on Aging (grant number NIH R01AG018016). Data files and documentation are public use and available at www.MHASweb.org.

## Consent for publication

NA.

## Competing interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. There was no founding for this work, and we declare that there was no conflict of interest.

## Author details

Received: 21 July 2020 Accepted: 12 October 2020

Published online: 23 October 2020

## References

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513-30.

2. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA, et al. Prevalencia de diabetes por diagnóstico médico previo en México. Salud Publica Mex. 2018;60:224-32.

3. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390:2673-734.

4. Mukadam N, Sommerland A, Huntley J, et al. Population attributable fractions for risk factors for dementia in low-income and middle-income countries: an analysis using cross-sectional survey data. Lancet Glob Health. 2019;7:e596-603.

5. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes systematic overview of prospective observational studies. Diabetologia. 2005;48:2460-9.

6. Ott A, Stolk RP, van Harskamp F, Pols HA, et al. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology. 1999;53(9):1937-42.

7. Velayudhan L. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry. 2010;196:36-40.

8. Mejía-Arango S, Zúñiga-Gil C. Diabetes mellitus Como factor de riesgo de demencia en la población adulta mayor mexicana. Rev Neurol. 2011;53:397-405.

9. American Diabetes Association. 6. Glycemic targets: standards of medical Care in Diabetes 2019. Diabetes Care. 2019;42(Suppl. 1):S61-70 Available at: https://hyp.is/hQ0b7rO6Eemy96878HFnAg/care.diabetesjournals.org/content/42/Supplement_1/S61. Accessed 13 October 2019.

10. Munshi M. Cognitive dysfunction in older adults with diabetes: what a clinician needs to know. Diabetes Care. 2017;40:461-7.

11. Kirkman M, Jones-Briscoe N, Clark N, et al. Diabetes in older adults. J Am Geriatr Soc. 2012;60:2342-56.

12. Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011; 10:969-77.

13. Wong R, Michaels-Obregon A, Palloni A. Cohort health and aging study (MHAS). Int J Epidemiol. 2017;46:e2.

14. Kumar A, Wong R, Ottenbacher KJ, et al. Prediabetes, undiagnosed diabetes, and diabetes among Mexican adults: findings from the Mexican health and aging study. Ann Epidemiol. 2016;26:163-70.

15. MHAS: The Mexican Health and Aging Study [MHAS 2012 Data Files Description, Version 2 website]. Available at: http://www.mhasweb.org. Accessed 10 Sept 2019.

16. Strauss SM, Rosedale M, Pesce MA, et al. Point-of-care HbA1c testing with the A1cNow test kit in general practice dental clinics: a pilot study involving its accuracy and practical issues in its use. Point Care. 2014;13:142-7.

17. Glosser G, Wolfe N, Albert M, et al. Cross-cultural cognitive examination: validation of a dementia screening instrument for Neuroepidemiological research. J Am Geriatr Soc. 1993;41:931-9.

18. Mejía-Arango S, Wong R, Michaels-Obregón A. Normative and standardized data for cognitive measures in the Mexican health and aging study. Salud Publica Mex. 2015;57:90-6.

19. Bahat G, Tufan F, Saka B, et al. Which body mass index (BMI) is better in the elderly for functional status? Arch Gerontol Geriatr. 2012;54:78-81.

20. Aguilar-Navarro S, Fuentes-Cantú A, Ávila-Funes J, et al. Validez y confiabilidad del cuestionario del ENASEM Para la depresión en adultos mayores. Salud Publica Mex. 2007;49:256-62.

21. Exalto LG, Biessels GJ, Karter AJ, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol. 2013;1:183-90.

22. Rawlings AM, Sharrett AR, Albert MS, et al. The Association of Late-Life Diabetes Status and Hyperglycemia with incident mild cognitive impairment and dementia: the ARIC study. Diabetes Care. 2019;42:1248-54.

<footnote n="1">¹Geriatric Medicine & Neurology Fellowship, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, 14000 Mexico City, Mexico.</footnote>

<footnote n="2">²Department of Geriatric Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Vasco de Quiroga 15. Tlalpan, 14000 Mexico City, Mexico.</footnote>
23. Koekkoek PS, Ruis C, Van Den Donk M, et al. Intensive multifactorial treatment and cognitive functioning in screen-detected type 2 diabetes - the ADDITION-Netherlands study: a cluster-randomized trial. Neurol Sci. 2012;314:71-7.

24. De Galan BE, Zoungas S, Chalmers J, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the action in diabetes and vascular disease: preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia. 2009; 52:2328-36.

25. Tuligenga RH. Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. Endocr Connect. 2015;41:R16-24.

26. Morley JE. Diabetes: the diabetic brain. Nat Rev Endocrinol. 2017;13:570-1.

27. Tabit CE, Chung WB, Hamburg NM, et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications. Rev Endocr Metab Disord. 2010;11:61-74.

28. Murman DL. The impact of age on cognition. Semin Hear. 2015;36:111-21.

29. Wheeler MJ, Dempsey PC, Grace MS, et al. Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health. Alzheimers Dement (N Y). 2017;3:291-300.

30. Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015;1353:60-71.

31. Schimming C, Luo X, Zhang C, et al. Cognitive performance of older adults in a specialized diabetes clinic. J Diabetes. 2017;9:929-35.

32. Lalithambika CV, Arun CS, Saraswathy LA, et al. Cognitive impairment and its association with glycemic control in type 2 diabetes mellitus patients. Indian J Endocr Metab. 2019;23:353-6.

33. Zheng F, Yan L, Yang Z, et al. HbA1c, diabetes and cognitive decline: the English longitudinal study of ageing. Diabetologia. 2018;61:839-48.

34. Mordarska K, Godziejewska-Zawada M. Diabetes in the elderly. Prz Menopauzalny. 2017;16:38-43.

35. Liu M, Wang J, He Y, et al. Awareness, treatment and control of type 2 diabetes among Chinese elderly and its changing trend for past decade. BMC Public Health. 2016;16:278.

36. Custodio N, Wheelock A, Thumala D, et al. Dementia in Latin America: epidemiological evidence and implications for public policy. Front Aging Neurosci. 2017;9:221.

37. Cheng ST. Cognitive reserve and the prevention of dementia: the role of physical and cognitive activities. Curr Psychiatry Rep. 2016;18:85.

38. Khattab M, Khader YS, Al-Khawaldeh A, et al. Factors associated with poor glycemic control among patients with type 2 diabetes. J Diabetes Complicat. 2010;24:84.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

* fast, convenient online submission

* thorough peer review by experienced researchers in your field

* rapid publication on acceptance

* support for research data, including large and complex data types

* gold Open Access which fosters wider collaboration and increased citations

* maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

BMC